Qilian International Holding Group Limited Net Assets
Qilian International Holding Group Limited net assets. Based on the latest financial reports, Qilian International Holding Group Limited (BGM) has net assets worth $399.98 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($436.55 Million) and total liabilities ($36.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Qilian International Holding Group Limit equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $399.98 Million |
| % of Total Assets | 91.62% |
| Annual Growth Rate | 52.15% |
| 5-Year Change | 591.99% |
| 10-Year Change | N/A |
| Growth Volatility | 255.65 |
Net Assets of Qilian International Holding Group Limited (2017–2025)
Net assets of Qilian International Holding Group Limited from 2017 to 2025. This chart illustrates how Qilian International Holding Group Limited's net assets have evolved over time, based on quarterly financial data. See BGM equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Qilian International Holding Group Limited (2017–2025)
The table below shows the annual net assets of Qilian International Holding Group Limited from 2017 to 2025. For live market cap and overall valuation, see Qilian International Holding Group Limit (BGM) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $392.14 Million | +789.34% |
| 2024-09-30 | $44.09 Million | -0.58% |
| 2023-09-30 | $44.35 Million | -19.31% |
| 2022-09-30 | $54.96 Million | -3.01% |
| 2021-09-30 | $56.67 Million | +96.48% |
| 2020-09-30 | $28.84 Million | +27.40% |
| 2019-09-30 | $22.64 Million | +27.74% |
| 2018-09-30 | $17.72 Million | +29.76% |
| 2017-09-30 | $13.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Qilian International Holding Group Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 616.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Qilian International Holding Group Limited Net Assets Breakdown (September 2025)
Qilian International Holding Group Limited net assets breakdown by equity component as of September 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.67 Million | 0.43% |
| Other Comprehensive Income | $5.97 Million | 1.53% |
| Other Components | $399.02 Million | 102.08% |
| Total Equity | $390.88 Million | 100.00% |
Qilian International Holding Group Limited Competitors by Market Cap
The table below lists competitors of Qilian International Holding Group Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
John Hancock Investors Closed Fund
NYSE:JHI
|
$105.37 Million |
|
Daishin Securities Co Ltd Pref 2
KO:003547
|
$105.38 Million |
|
Nien Hsing Textile Co Ltd
TW:1451
|
$105.42 Million |
|
TuHURA Biosciences Inc
NASDAQ:HURA
|
$105.47 Million |
|
Europen Endustri Insaat Sanayi ve Ticaret A.S.
IS:EUREN
|
$105.36 Million |
|
HMCIB SPAC 3
KQ:226340
|
$105.34 Million |
|
An Phat Plastic and Green Environment JSC
VN:AAA
|
$105.32 Million |
|
The Century Co., Ltd.
KO:002420
|
$105.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Qilian International Holding Group Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 42,743,844 to 390,878,117, a change of 348,134,273 (814.5%).
- Net loss of 19,941,242 reduced equity.
- Other comprehensive income increased equity by 4,042,517.
- Other factors increased equity by 364,032,998.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.94 Million | -5.1% |
| Other Comprehensive Income | $4.04 Million | +1.03% |
| Other Changes | $364.03 Million | +93.13% |
| Total Change | $- | 814.47% |
Book Value vs Market Value Analysis
This analysis compares Qilian International Holding Group Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.76x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.94x to 2.76x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-09-30 | $1.61 | $9.54 | x |
| 2018-09-30 | $2.19 | $9.54 | x |
| 2019-09-30 | $2.84 | $9.54 | x |
| 2020-09-30 | $3.73 | $9.54 | x |
| 2021-09-30 | $8.05 | $9.54 | x |
| 2022-09-30 | $7.34 | $9.54 | x |
| 2023-09-30 | $5.92 | $9.54 | x |
| 2024-09-30 | $5.91 | $9.54 | x |
| 2025-09-30 | $3.45 | $9.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Qilian International Holding Group Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -52.59%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 1.11x
- Recent ROE (-5.10%) is below the historical average (8.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 12.58% | 6.28% | 0.68x | 2.97x | $290.45K |
| 2018 | 33.74% | 10.26% | 1.51x | 2.18x | $3.64 Million |
| 2019 | 26.80% | 11.57% | 1.31x | 1.77x | $3.34 Million |
| 2020 | 19.40% | 10.12% | 1.04x | 1.84x | $2.45 Million |
| 2021 | 5.75% | 5.52% | 0.76x | 1.37x | $-2.33 Million |
| 2022 | 2.03% | 1.66% | 1.01x | 1.22x | $-4.23 Million |
| 2023 | -18.18% | -16.74% | 0.91x | 1.20x | $-12.06 Million |
| 2024 | -3.38% | -5.75% | 0.47x | 1.24x | $-5.72 Million |
| 2025 | -5.10% | -52.59% | 0.09x | 1.11x | $-59.03 Million |
Industry Comparison
This section compares Qilian International Holding Group Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $86,713,726
- Average return on equity (ROE) among peers: 26.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Qilian International Holding Group Limited (BGM) | $399.98 Million | 12.58% | 0.09x | $105.36 Million |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.57% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $335.50 Million | -73.41% | 0.53x | $143.73 Million |
| Akanda Corp (AKAN) | $4.28 Million | -95.78% | 0.85x | $584.11K |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $194.43 Million |
| Alkermes Plc (ALKS) | $18.84 Million | -398.98% | 9.71x | $7.67 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.25 Billion |
| Amphastar P (AMPH) | $233.44 Million | 7.75% | 0.36x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $5.96 Million | 1208.40% | 615.85x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $135.63 Million | 15.17% | 0.15x | $260.30 Million |
About Qilian International Holding Group Limited
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and… Read more